These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30729850)

  • 1. The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors.
    Seetasith A; Wong W; Tse J; Burudpakdee C
    J Med Econ; 2019 May; 22(5):414-420. PubMed ID: 30729850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer.
    Sheinson D; Wong WB; Wu N; Mansfield AS
    Lung Cancer; 2020 May; 143():86-92. PubMed ID: 32276206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copay assistance use and prescription abandonment across race, ethnicity, or household income levels for select rheumatoid arthritis and oral oncolytic medicines.
    Wong WB; Donahue A; Thiesen J; Yeaw J
    J Manag Care Spec Pharm; 2023 Mar; 29(3):324-334. PubMed ID: 36692908
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents.
    Doshi JA; Li P; Huo H; Pettit AR; Armstrong KA
    J Clin Oncol; 2018 Feb; 36(5):476-482. PubMed ID: 29261440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy.
    Navar AM; Taylor B; Mulder H; Fievitz E; Monda KL; Fievitz A; Maya JF; López JAG; Peterson ED
    JAMA Cardiol; 2017 Nov; 2(11):1217-1225. PubMed ID: 28973087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of racial and ethnic inequities in copay card utilization and enrollment in copay adjustment programs.
    Ingham M; Sadik K; Zhao X; Song J; Fendrick AM
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1084-1092. PubMed ID: 37548953
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of Out-of-Pocket Cost on Medication Initiation, Adherence, and Persistence among Patients with Type 2 Diabetes: The Diabetes Study of Northern California (DISTANCE).
    Karter AJ; Parker MM; Solomon MD; Lyles CR; Adams AS; Moffet HH; Reed ME
    Health Serv Res; 2018 Apr; 53(2):1227-1247. PubMed ID: 28474736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
    Duruisseaux M; Besse B; Cadranel J; Pérol M; Mennecier B; Bigay-Game L; Descourt R; Dansin E; Audigier-Valette C; Moreau L; Hureaux J; Veillon R; Otto J; Madroszyk-Flandin A; Cortot A; Guichard F; Boudou-Rouquette P; Langlais A; Missy P; Morin F; Moro-Sibilot D
    Oncotarget; 2017 Mar; 8(13):21903-21917. PubMed ID: 28423535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy.
    Guérin A; Sasane M; Wakelee H; Zhang J; Culver K; Dea K; Nitulescu R; Galebach P; Macalalad AR
    Curr Med Res Opin; 2015 Aug; 31(8):1587-97. PubMed ID: 26029864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer.
    Zheng N; Zhang Y; Zeng Y; Ma Q; Zhang R; Zhao Q; Lu C; Tian J; Wang Z; Tang H; Luo N; Xiao H; He Y; Wu F; Li L
    Target Oncol; 2023 Jul; 18(4):625-636. PubMed ID: 37351800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
    Califano R; Greystoke A; Lal R; Thompson J; Popat S
    Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.
    Gleason PP; Starner CI; Gunderson BW; Schafer JA; Sarran HS
    J Manag Care Pharm; 2009 Oct; 15(8):648-58. PubMed ID: 19803554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Financial Toxicity in Oncology Specialty Pharmacy at a Large Tertiary Academic Medical Center.
    Farano JL; Kandah HM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):765-769. PubMed ID: 31232209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review.
    Kassem L; Shohdy KS; Lasheen S; Abdel-Rahman O; Ali A; Abdel-Malek RR
    Crit Rev Oncol Hematol; 2019 Feb; 134():56-64. PubMed ID: 30771874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in a mid-size integrated health system.
    Brouwer E; Yeung K; Barthold D; Hansen R
    J Manag Care Spec Pharm; 2021 Jun; 27(6):732-742. PubMed ID: 34057391
    [No Abstract]   [Full Text] [Related]  

  • 16. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
    Golding B; Luu A; Jones R; Viloria-Petit AM
    Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.
    Lu S; Yu Y; Fu S; Ren H
    PLoS One; 2018; 13(10):e0205827. PubMed ID: 30352060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Associated with Adherence to and Treatment Duration of Erlotinib Among Patients with Non-Small Cell Lung Cancer.
    Hess LM; Louder A; Winfree K; Zhu YE; Oton AB; Nair R
    J Manag Care Spec Pharm; 2017 Jun; 23(6):643-652. PubMed ID: 28530522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
    Toyokawa G; Seto T; Takenoyama M; Ichinose Y
    Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient perceptions of copay card utilization and policies.
    Cavalier D; Doherty B; Geonnotti G; Patel A; Peters W; Zona S; Shea L
    J Mark Access Health Policy; 2023; 11(1):2254586. PubMed ID: 37692554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.